AP5346 [ProLindac; Access Pharmaceuticals] for recurrent/unresectable squamous cell carcinoma of the head and neck: a pilot study with clinical and biological endpoints

Next Previous
Trial Profile

AP5346 [ProLindac; Access Pharmaceuticals] for recurrent/unresectable squamous cell carcinoma of the head and neck: a pilot study with clinical and biological endpoints

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2006

At a glance

  • Drugs AP 5346; Oxaliplatin
  • Indications Head and neck cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 18 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top